Published in Cancer Res on June 01, 1983
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. J Virol (1985) 1.59
Immune responses to malignancies. J Allergy Clin Immunol (2010) 1.48
Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer (1996) 1.03
Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol (2006) 0.99
Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br J Cancer (1997) 0.99
HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest (1984) 0.97
Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. Immunology (1985) 0.88
Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Ann Surg (1985) 0.87
DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol (1988) 0.86
Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinomas. Br J Cancer (1987) 0.83
Identification of lymphocyte subsets and natural killer cells in head and neck cancers. An immunohistological study using monoclonal antibodies. Arch Otorhinolaryngol (1985) 0.80
Macrophages in melanocytic naevi. Arch Dermatol Res (1992) 0.75
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Antibody NCL-CD5 fails to detect neoplastic CD5+ cells in paraffin sections. Am J Clin Pathol (1996) 2.67
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Leiomyomatous neoplasms of the lung: a clinical, histologic, and immunohistochemical study. Mod Pathol (1989) 2.32
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med (1995) 2.15
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc (1999) 1.96
A murine model for oral infection with a primate rotavirus (simian SA11). J Virol (1984) 1.91
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Malignant "Triton" tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer (1985) 1.84
Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Pressure-dependent metallic and superconducting phases in a germanium artificial metal. Phys Rev Lett (2009) 1.73
Extraadrenal myelolipoma: MR imaging findings. AJR Am J Roentgenol (1998) 1.73
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Functionalized pentacene: improved electronic properties from control of solid-state order. J Am Chem Soc (2001) 1.59
Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. J Virol (1985) 1.59
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol (1994) 1.53
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol (1996) 1.47
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Primary cutaneous osteosarcoma. Am J Dermatopathol (1995) 1.43
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol (1993) 1.39
Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res (1994) 1.38
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Diabetic mastopathy: a distinctive clinicopathologic entity. Hum Pathol (1992) 1.29
Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ (1995) 1.28
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol (1997) 1.23
Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol (1993) 1.23
MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol (2001) 1.21
Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol (1988) 1.20
Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene (2007) 1.19
HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab Invest (1998) 1.17
Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg (2001) 1.15
Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol (1996) 1.14
MCM2--a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer (2001) 1.14
Pigmented villonodular synovitis of a lumbar facet joint. AJNR Am J Neuroradiol (1992) 1.14
Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol (1999) 1.13
Thymoma classification: my opinion. Am J Clin Pathol (1999) 1.12
Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet (1980) 1.12
When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA (1984) 1.12
Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol (1994) 1.11
Gastroenteritis caused by human rotaviruses (serotype three) in a suckling mouse model. Proc Soc Exp Biol Med (1987) 1.11
Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol (1984) 1.11
Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. Mod Pathol (1994) 1.06
Expression of DR antigens in freshly frozen human tumors. Hybridoma (1982) 1.05
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04
Lymphatic vessel density is significantly increased in melanoma. J Cutan Pathol (2004) 1.03
Lipofibromatous hamartomas of the median nerve. J Hand Surg Am (1993) 1.03
Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol (1993) 1.02
Dysplastic naevi and cutaneous melanoma risk. Lancet (1983) 0.99
Specificity of HMB-45. Arch Pathol Lab Med (1990) 0.98
Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr (1983) 0.98
Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol (1990) 0.97
Vortex dynamics and the Fulde-Ferrell-Larkin-Ovchinnikov state in a magnetic-field-induced organic superconductor. Phys Rev Lett (2006) 0.96
The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg (1991) 0.96
Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer (1995) 0.95
Immunohistology of human thymomas. Arch Pathol Lab Med (1985) 0.95
Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. J Cutan Pathol (1999) 0.95
Risk of cutaneous melanoma in dysplastic nevus syndrome types A and B. N Engl J Med (1986) 0.93
Proximity detector circuits: an alternative to tunnel diode oscillators for contactless measurements in pulsed magnetic field environments. Rev Sci Instrum (2009) 0.93
Malignant lymphoma imitating hepatitis. Cancer (1993) 0.92
Dysplastic naevi in a population-based survey. Cancer (1989) 0.92
Growth regulation of cultured human nevus cells. J Invest Dermatol (1993) 0.92
Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer (1993) 0.91
Leukophagocytosis by Reed-Sternberg cells in Hodgkin's disease. N Engl J Med (1979) 0.91
Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol (1987) 0.91
Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res (1987) 0.91
UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol (1998) 0.91
Effects of topical tretinoin on dysplastic nevi. J Clin Oncol (1994) 0.91
CD5 immunoreactivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Am J Clin Pathol (1996) 0.91
Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol (1991) 0.90
Long-term results of breast conservation therapy for breast cancer. Ann Surg (1996) 0.90
Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol (1987) 0.89
Natural history of dysplastic nevi. J Am Acad Dermatol (1993) 0.89
Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female. Clinical and immunologic findings. Cancer (1991) 0.89
A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol (1993) 0.89
PEComa of the Upper Extremity: A Unique Case and Description of an Initial Response to Neoadjuvant Chemotherapy. Sarcoma (2007) 0.89
The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer (1985) 0.88
Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg (2001) 0.88
Malignant lymphoma can present as hepatobiliary disease. Cancer (1996) 0.88
Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res (2002) 0.88
Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer (1994) 0.88